THE DARK REPORT
21806 Briarcliff Dr.
Spicewood, Texas 78669
FOR IMMEDIATE RELEASE
Media Contact: Ron Martin
AUSTIN, Texas (February 16, 2015) – Pharmacogenomic testing, or PGx, is the study of how an individual’s genetic makeup affects their response to drugs. Through the use of PGx, patient-specific genomic markers are used to select the appropriate treatment for ensuring drug efficacy, while minimizing the risk of toxicity.
“Although the value of PGx testing is clear, it presents a number of challenges to physicians, clinical diagnostic laboratories, and healthcare institutions,” states Robert L. Michel, Editor-In-Chief of The Dark Report. “A primary challenge is the difficulty of analyzing the complex amount of information involved in PGx testing, and then turning that information into actionable intelligence that a busy physician can use to drive good medical care—and to do so in a cost-effective, efficient, and reliable manner.”
One potential solution is to invest in an outsourced, cloud-based PGx interpretation service, which allows for numerous advantages, including faster time to implementation, quicker turnaround times and more consistent end results, in addition to lower investment risk and an ultimate lower overall cost. Addressing this important topic is a recently published white paper from The Dark Report, entitled “A Lab Leader’s Guide to Pharmacogenomic Testing (PGx): Cloud-Based Software Reporting of PGx for Hospitals, Health Systems and Clinical Laboratories.” Published by The Dark Report and Dark Daily, it is available free to laboratory professionals as a PDF download.
This free white paper provides a greater understanding of the obstacles physicians, laboratories and hospitals face when launching a pharmacogenomics program, how PGx testing can be used to drive patient care, and the important role cloud-based software can play in making PGx testing a practical and cost-effective solution.
White paper topics specifically addressed include:
- The ways in which pharmacogenomics can lead to an ultimate overall decrease in healthcare costs
- Myriad benefits that pharmacogenomics testing can provide patients
- How numerous studies support the clinical usefulness of PGx testing
- Various barriers to entry into the pharmacogenomic testing market
- Outsourcing as a solution to making PGx testing a viable option for laboratories
- The many advantages to a service that specializes in PGx interpretation
- Today’s status of genomic testing in the lab market, and what the future may hold
For an enlightening overview of pharmacogenomic testing and how PGx fits into current and future healthcare goals, and examples of how a cloud-based, Software-as-a-Service platform can help healthcare providers overcome obstacles encountered when considering entering the pharmacogenomic testing market, click here. “A Lab Leader’s Guide to Pharmacogenomic Testing (PGx): Cloud-Based Software Reporting of PGx for Hospitals, Health Systems and Clinical Laboratories” is a free publication and part of the Dark Daily Resource Center, comprised of a growing library of white papers and other information resources tailored specifically to the needs of laboratory administrators, lab managers, pathologists, and lab industry consultants.
For additional information, Contact: Ron Martin, 512-264-7103
About THE DARK REPORT
Established in 1995, THE DARK REPORT is the leading source of exclusive business intelligence for laboratory CEOs, COOs, CFOs, Pathologists and Senior industry executives. It is widely read by leaders in laboratory medicine and diagnostics. The Dark Report produces the famous Executive War College on Laboratory and Pathology Management every spring, which showcases innovations by the nation’s and globe’s leading laboratory organizations. Dark Daily is an Internet-based e-briefing intelligence service, read worldwide by thought leaders in laboratory and pathology management. Other well-known conferences conducted by THE DARK REPORT are Lab Quality Confab (on the use of Lean and Six Sigma methods in labs and hospitals), Molecular Summit (on the integration of in vivo and in vitro diagnostics). THE DARK REPORT co-produces Frontiers in Laboratory Medicine annually in the United Kingdom; Executive Edge bi-annually in Canada; and The Business of Pathology bi-annually in Australia.